AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M

Core Insights - AbCellera Biologics Inc. has transitioned into a clinical-stage biotechnology company, reporting total revenue of $75 million for 2025, with a net loss of $146 million [1][2]. Financial Performance - The company's revenue breakdown includes $27 million from partnered programs and $48 million from licensing and royalties [1]. - The reported net loss of $146 million reflects a strategic shift towards internal pipeline development, supported by a $187 million investment in R&D [2]. Clinical Pipeline Development - AbCellera's lead program, ABCL635, has advanced to Phase 2 studies for vasomotor symptoms, with a major readout expected in Q3 2026 [2]. - The second lead program, ABCL575, is currently in Phase 1 trials, with data anticipated by the end of the year [3]. Manufacturing and Supply Chain - The company is nearing completion of its own clinical manufacturing facility, which will enhance control over its supply chain and proprietary technology [3]. Strategic Focus - AbCellera is reducing transparency on partner-initiated program starts by moving to less frequent reporting, while concentrating on internal first-in-class programs in oncology and immunology [3].